Compare Costco Wholesale Corporation (COST) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Summit Therapeutics Inc — how do they compare? Costco Wholesale Corporation trades at $916.5 (market cap $408.78B), while Summit Therapeutics Inc trades at $15.01 (market cap $12.01B). The key difference: Costco Wholesale Corporation is far larger — about 34× Summit Therapeutics Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| COST | SMMT | |
|---|---|---|
Market Cap | $408.78B | $12.01B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $29.32 |
52-Week Low | $849.63 | $13.05 |
Enterprise Value | $396.92B | $11.43B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $916.54, down 1.07% with a bearish technical signal. The company shows strong fundamentals with revenue growth from $275.24B in 2025 to projected $293.6B in 2026 and consistent earnings beats in recent quarters. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,120 price target, though valuation metrics appear elevated with a P/E of 46.37. Recent March sales surged 11.3% year-over-year, demonstrating resilient consumer demand despite market volatility.
The outlook remains positive given Costco's membership fee growth and expansion strategy, but risks include premium valuation compression and competitive pressures. With strong institutional accumulation and solid cash flow generation, COST offers long-term growth potential for investors comfortable with current multiples. The stock's current pullback near support at $917 may present an entry opportunity for patient investors.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
